Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Biomaterials. 2016 Jun 9;101:321–340. doi: 10.1016/j.biomaterials.2016.06.018

Fig. 5.

Fig. 5

Oral administration of GDNPs does not induce side effects at the local or systemic level. Mice (N=5) were oral administrated with GDNPs 2 of 0.3 mg/day for 7 days. (A) Colonic myeloperoxidase (MPO) activity. (B) Quantify proinflammatory cytokines (TNF-α, IL-6 and IL-1β) at mRNA level. (C) Quantify proinflammatory cytokines (TNF-α, IL-6 and IL-1β) at protein level. (D) H&E stain, IEC proliferation and IEC apoptosis examination in colonic tissues. Scale Bar=100 μm. (n=5).